The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. These four healthcare stocks are well-positioned as the nation recovers from Covid-19.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).
The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses.
Americans will receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines.
USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, recently announced the launch of QHSLab, a Software as a Service (SaaS) platform.
QHSLab will be brought to the marketplace through approximately 150 primary care practices in Florida. Physicians, nurse practitioners, and ancillary medical practice staff will be active users of this platform, utilizing its proprietary algorithm initially for selecting appropriate allergen immunotherapy treatment sets for their patient populations.
Primary care physicians are overwhelmed by the number of patients suffering from allergies. Allergies often signal other health related concerns, indicating an immune system that is going wrong. Doctors need easy-to-use, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. Through our AI-enhanced, physician-directed platform, QHSLab, we are increasing the primary care physicians ability to more effectively address the issues with their patients, while saving patients time and expensive visits to a specialist when not absolutely necessary,” said Troy Grogan, President and CEO of Medical Practice Income, Inc.
With the addition of QHSLab, not only will physicians be better equipped to treat patients, but they will also be able to sustain their practices with ongoing revenue through healthcare reimbursements, generating much needed new income per practice, per year.
Gilead Sciences, Inc. (NASDAQ: GILD) announced that it will acquire a 49.9% equity interest in Tizona Therapeutics, Inc., a privately-held developer of first-in-class cancer immunotherapies, for $300 million. In addition, Gilead will have an exclusive option to buy the rest of the company for up to $1.25 billion. This option will include an option exercise fee and potential future milestone payments.
Tizona develops first-in-class medicines to bring in transformations for people suffering from cancer. Its lead pipeline candidate is TTX-080. TTX-080 is a potential first-in-class medicine that targets HLA-G. The characteristic of HLA-G is that it can address tumors that do not respond to current anti-PD-(L)1 treatments. It also deepens responses in tumors that are sensitive to anti-PD-(L)1 therapies.